TheStreet downgraded the shares of ACOR in report on Tuesday, August 25 to "Buy" rating. Several analysts recently issued reports on the stock. BidaskClub raised shares of Acorda Therapeutics from a "buy" rating to a "strong-buy" …
The fund owned 2,712 shares of the entertainment giant's stock at the end of the first quarter. It has underperformed by 7.44% the S&P500. Spark Investment …
The stock increased 0.41% or $0.45 during the last trading session ... Spark …
On November 4, 2016 the stock rating was set at "Overweight" by JP Morgan …
Its lead drug candidate, CVT-301, shows strong potential. The company stock is priced attractively after a sudden slump in its value. Acorda Therapeutics Inc. (NASDAQ:ACOR) stock shows a strong recovery from its April slump, which erased …
Acorda Therapeutics, Inc. (ACOR - Free Report) reported adjusted earnings of 6 cents per share in the second quarter of 2017 (including the impact of stock
Acorda Therapeutics stock is trading 10% higher today at $16.79, getting a boost after positive data on CVT-301, the company's Parkinson's drug. ACOR stock has had a rough year, touching a 10-year low of $13.60 on June 1, and …
Barry E Greene , Director of Acorda Therapeutics, Inc. (NASDAQ:ACOR) reportedly Sold 10,000 shares of the …
It is trading at $21.70 which is marginally over $19.72, the 50 day moving average and marginally over the 200 day …
Some of the biggest gainers among healthcare stocks include: Acorda Therapeutics (ACOR): ACOR stock is up 2.8%, marking the third consecutive day the stock has increased. Universal Health Services (UHS): UHS stock is up 2.7% to …